ABBV-744

DRUG2 trials

Sponsors

AbbVie

Conditions

Acute Myeloid Leukemia (AML)Myelofibrosis (MF)

Phase 1

A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Participants With Relapsed/Refractory Acute Myeloid Leukemia (AML) Cancer

TerminatedNCT03360006

AbbVieAcute Myeloid Leukemia (AML)

Start: 2018-03-16End: 2020-12-19Updated: 2021-03-24

Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis

Active, not recruitingNCT04454658

AbbVieMyelofibrosis (MF)

Start: 2020-11-11End: 2027-01-31Updated: 2025-07-16

Related Papers

Phase 1b study of ABBV-744, a novel, selective BET inhibitor, as monotherapy in patients with myelofibrosis.

2026-03-17

Acute Myeloid Leukemia (AML) With T-Cell Differentiation Arising From Chronic Myelomonocytic Leukemia (CMML).

2024-12-14

PB2224: ABBV-744 ALONE OR IN COMBINATION WITH RUXOLITINIB OR NAVITOCLAX IN PATIENTS WITH MYELOFIBROSIS: A PHASE 1B STUDY

HemaSphere2023-08-011 citations

Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia

Molecular Cancer Therapeutics2021-07-1232 citations

Two Phase 1b Studies Evaluating the Safety and Tolerability of BET Inhibitors, ABBV-744 and Mivebresib, as Monotherapies and in Combination with Ruxolitinib or Navitoclax in Patients with Myelofibrosis

Blood2020-11-047 citations

Selective Targeting BET Family Bdii Bromodomain with Abbv-744 and BCL-2 with Venetoclax (ABT-199) Is Synergistic in Primary Acute Myeloid Leukemia Models

Blood2019-11-132 citations